Loading organizations...
Loading organizations...
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines across various therapeutic areas. The company leverages a diversified pipeline, including small molecules and biologics, with a particular emphasis on its orexin receptor 2 (OX2R) agonists for sleep-wake disorders and its LockBody® Technology Platform for targeted oncology treatments, progressing programs from discovery through late-stage development.
The company's foundational efforts are significantly tied to Mario Alberto Accardi, who is recognized as a founder of Centessa's Orexin Program and now serves as its Chief Executive Officer. Centessa was established with the vision of assembling a portfolio of high-potential assets and programs from various academic and industry sources, consolidating them into a single entity to accelerate drug development. This approach aimed to bring forward promising compounds more efficiently.
Centessa's therapeutic developments target patients suffering from significant unmet medical needs, such as those with sleep-wake disorders and various cancers. The company's overarching vision is to deliver medicines that can provide substantial, life-changing benefits to patients. It maintains a forward-looking strategy focused on advancing its diverse pipeline to realize these transformational health outcomes.
Centessa Pharmaceuticals has raised $250.0M across 1 funding round.
Centessa Pharmaceuticals has raised $250.0M in total across 1 funding round.
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company, not a technology company in the traditional software or hardware sense, focused on discovering and developing transformational medicines for patients with sleep-wake disorders, neurological conditions, and cancer.[1][2][3] It builds potential best-in-class orexin receptor 2 (OX2R) agonists—orally administered drugs targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), impaired attention, cognitive deficits, fatigue, and other neuropsychiatric symptoms—alongside an early-stage immuno-oncology program using the LockBody® technology platform.[2] Serving patients with unmet needs in neuroscience and oncology, Centessa addresses critical gaps in treatments for excessive daytime sleepiness and solid tumors by leveraging structure-based drug design and antibody engineering innovations.[1][2] Recent growth includes a CEO transition to expand orexin leadership into multiple neuroscience indications, a $250 million public offering, and headquarters completion in Boston.[1][3]
Centessa Pharmaceuticals emerged as a next-generation biotech with a research and development innovation engine, though specific founding year and founders are not detailed in available sources.[3][4] Key leaders include Dr. Mario Alberto Accardi, President of the Orexin Program and a biomedical engineer who pioneered structure-based drug design to rethink sleep-wake disorder treatments, and Dr. William Finlay, President of the LockBody Program and an antibody engineering expert who developed the LockBody® platform for immuno-oncology.[2] The company's idea stemmed from identifying unique medical needs: Accardi disrupted conventional approaches to orexin agonists for neurological conditions, while Finlay aimed to redefine cancer treatments, leading to a portfolio of innovative assets and data-driven R&D.[2][4] Early traction is marked by advancing clinical-stage programs and recent financing milestones like the $250 million offering.[1]
Centessa rides the trend of precision neuroscience and immuno-oncology, where structure-based drug design and antibody platforms enable targeted therapies for underserved conditions like narcolepsy and cancer, amid rising demand for oral treatments over invasives like hypocretin replacement.[2] Timing aligns with growing recognition of orexin pathways in sleep-wake regulation and neurodegeneration, fueled by market forces such as aging populations, post-pandemic sleep disorder surges, and immuno-oncology breakthroughs.[1][2] By influencing the ecosystem through its innovation engine and programs like OX2R agonists and LockBody®, Centessa contributes to biotech's shift toward multimodal neuroscience solutions, potentially setting standards for oral agonists in neuropsychiatric care.[2][4]
Centessa is poised to advance its orexin program into clinical trials across neuroscience indications, leveraging recent $250M funding and leadership changes for pipeline expansion, while maturing LockBody® toward oncology proofs-of-concept.[1][2] Trends like AI-driven drug design and personalized neurology will shape its path, amplifying structure-based innovations amid biotech's focus on brain health and cancer. Its influence may evolve by pioneering oral orexin therapies, transforming patient outcomes in sleep and neuro disorders, and tying back to its mission of delivering impactful, best-in-class medicines.[1][2][4]
Centessa Pharmaceuticals has raised $250.0M in total across 1 funding round.
Centessa Pharmaceuticals's investors include General Atlantic, Vida Ventures, Janus Henderson Investors, Atlas Venture, Boxer Capital, BVF Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, LifeSci Venture Partners, Logos Capital, Samsara BioCapital.
Centessa Pharmaceuticals has raised $250.0M across 1 funding round. Most recently, it raised $250.0M Series A in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $250.0M Series A | General Atlantic, Vida Ventures, Janus Henderson Investors | Atlas Venture, Boxer Capital, BVF Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, LifeSci Venture Partners, Logos Capital, Samsara BioCapital, T. Rowe Price Associates, Venrock, Wellington Management |
